Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

ADMA - ADMA Biologics Inc Stock Price, Fair Value and News

$21.86-0.47 (-2.10%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

ADMA Price Action

Last 7 days

2.6%

Last 30 days

11.0%

Last 90 days

35.9%

Trailing 12 Months

239.4%

ADMA RSI Chart

AugSepOctNovDec2025FebMarApr102030405060708090

ADMA Valuation

Market Cap

5.2B

Price/Earnings (Trailing)

26.28

Price/Sales (Trailing)

12.18

EV/EBITDA

38.06

Price/Free Cashflow

47.03

ADMA Price/Sales (Trailing)

20222023202420252468101214

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ADMA Fundamentals

ADMA Revenue

Revenue (TTM)

426.5M

Rev. Growth (Yr)

59.06%

Rev. Growth (Qtr)

-1.91%

20122014201620182020202220240100M200M300M400M

ADMA Earnings

Earnings (TTM)

197.7M

Earnings Growth (Yr)

734.17%

Earnings Growth (Qtr)

211.61%

201020152020-50M050M100M150M200M

ADMA Profitability

Operating Margin

51.48%

EBT Margin

29.48%

Return on Equity

56.64%

Return on Assets

40.45%

Free Cashflow Yield

2.13%

ADMA Investor Care

Shares Dilution (1Y)

4.61%

Diluted EPS (TTM)

0.82

ADMA Alerts

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2012201420162018202020222024050M100M150M200M250M300M350M400M450M
Net sales
YearQ1Q2Q3Q4
2024283.2M330.2M382.8M426.5M
2023181.9M208.1M234.3M258.2M
2022122.6M138.7M159.1M154.1M
202148.1M58.1M68.5M109.6M
202036.2M37.0M40.1M42.2M
201916.5M18.8M21.8M29.6M
201824.2M25.4M24.9M17.0M
201711.2M12.3M14.1M22.8M
20167.8M8.8M9.8M10.7M
20155.9M5.7M6.2M7.2M
20143.8M4.6M4.9M5.9M
20131.9M2.4M3.2M3.1M
20121.7M1.5M1.3M1.1M
20110001.9M
20100000
Get all data in R, Python etc through our Historical Stock Data APIs

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
 CEO
 WEBSITEadmabiologics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES617

ADMA Biologics Inc Frequently Asked Questions

What is the ticker symbol for ADMA Biologics Inc? What does ADMA stand for in stocks?

ADMA is the stock ticker symbol of ADMA Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ADMA Biologics Inc (ADMA)?

As of Fri Apr 25 2025, market cap of ADMA Biologics Inc is 5.19 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADMA stock?

You can check ADMA's fair value in chart for subscribers.

Is ADMA Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether ADMA is over valued or under valued. Whether ADMA Biologics Inc is cheap or expensive depends on the assumptions which impact ADMA Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADMA.

What is ADMA Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 25 2025, ADMA's PE ratio (Price to Earnings) is 26.28 and Price to Sales (PS) ratio is 12.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADMA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ADMA Biologics Inc's stock?

In the past 10 years, ADMA Biologics Inc has provided 0.099 (multiply by 100 for percentage) rate of return.